Press Releases Subscribe to our News
Regulatory
Conversion of paid subscribed units and first day of trading with warrants of series TO3
ReleaseRegulatory
Biosergen resolves on a directed issue to underwriters in connection with the completed rights issue
ReleaseRegulatory
Members of the board of directors and management subscribe in ongoing rights issue
ReleaseRegulatory
Biosergen publishes interim report for fourth quarter 2023
ReleaseQ4-2023 Financial Report
Regulatory
Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection.
ReleaseRegulatory
Biosergen carries out a rights issue of units of approximately SEK 40.5 million, and secures bridge loan
ReleaseRegulatory
Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor
ReleaseRegulatory
Biosergen’s Partner Alkem Laboratories Submits Clinical Trial Application for First Patient Study with BSG005 in Invasive Fungal Infections in India as a Rescue Therapy
ReleaseRegulatory
Biosergen publishes interim report for third quarter 2023
ReleaseQ3-2023 Financial Report
Regulatory
Biosergen and Alkem Laboratories Ltd collaborates to develop anti-infective for severe fungal infections
ReleaseRegulatory
Warrants series TO2 were exercised to approximately 96.1 percent and Biosergen AB receives approximately SEK 5.5 million
ReleaseRegulatory
The last day of trading in warrants series TO2 in Biosergen AB is today, August 22, 2023
ReleaseRegulatory
Biosergen Receives Full Subscription Guarantees for Warrant Exercise from Largest Shareholders and Executive Management
ReleaseRegulatory
Biosergen publishes interim report for first quarter 2023
ReleaseQ2-2023 Financial Report
Regulatory
The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023
ReleaseRegulatory
Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11)
ReleaseRegulatory
Biosergen publishes interim report for first quarter 2023
ReleaseQ1-2023 Financial Report
Regulatory
Biosergen publishes interim report for fourth quarter 2022
ReleaseQ4-2022 Financial Report
Regulatory
Biosergen publishes interim report for third quarter 2022
ReleaseQ3-2022 Financial Report
Regulatory
Biosergen moves into the MAD (Multiple Ascending Dose) part of its phase I study after 4 cohorts tested in the SAD (Single Ascending Dose) part of the study.
ReleaseRegulatory
Biosergen AB: Biosergen’s Board of Directors decides on a rights issue of units of approximately SEK 60.2 million
ReleaseRegulatory
Biosergen publishes interim report for second quarter 2022
ReleaseQ2-2022 Financial Report
Regulatory
Announcement from the annual general meeting held on June 28, 2022 in Biosergen AB
ReleaseRegulatory
Biosergen publishes interim report for first quarter 2022
Release2022-Q1 Financial Report
Regulatory
Biosergen publishes interim report for fourth quarter 2021
Biosergen Q4 financial report press releaseQ4-2021 Financial Report
Regulatory
Biosergen publishes interim report for the third quarter 2021
Q3-2021 Financial ReportBiosergen Q3 financial report press release
Regulatory
Biosergen publishes interim report for the second quarter 2021
Q2-2021 Financial ReportBiosergen Q2 report press release
Regulatory
